ImmuneResearch Phase

Beta-Defensin 2

Topical, Subcutaneous injection

Overview

Beta-defensin 2 (hBD-2) is an antimicrobial peptide of approximately 40 amino acids produced by epithelial cells in response to infection or inflammation. It disrupts microbial membranes and also functions as a chemoattractant for immune cells via CCR6 receptor binding.

Mechanism of Action

Therapeutic interest includes infection control and immune adjuvant applications..

Research Summary & Key Findings

Preclinical studies have confirmed broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses, along with immunomodulatory properties. Clinical development of recombinant or synthetic beta-defensin 2 for topical or systemic use remains in early phases, with no advanced trials or approvals reported.

Clinical Status

Research Phase

Beta-Defensin 2 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

TopicalSubcutaneous injection

Related Peptides in Immune

Find a Provider

Find a verified provider who offers Beta-Defensin 2 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Beta-Defensin 2.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.